Business
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability. This adoption positions Hoth at the forefront of AI-driven drug development, reinforcing its commitment to cutting-edge innovation and accelerated therapeutic discovery.
About this update from Lantern Pharma Inc.
[{"type":"text","content":"NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability. This adoption positions Hoth at the forefront of AI-driven drug development, reinforcing its commitment to cutting-edge innovation and accelerated therapeutic discovery.","length":525,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hoth Therapeutics Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hoth Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":68,"url":"https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r2Ptel_Ut1tf_dA2SUFY0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb","width":400,"height":68}},"href":"https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"PredictBBB.ai, part of Lantern's RADR® AI platform, is a game-changing technology designed to eliminate one of the most significant bottlenecks in drug development: determining whether a candidate can cross the blood-brain barrier. By deploying this AI-driven solution, Hoth expects to streamline candidate selection, reduce development risk, and accelerate timelines toward transformative therapies.","length":409,"tagName":"p"},{"type":"text","content":""At Lantern Pharma, we're very enthused by the early adoption of our PredictBBB.ai platform by innovators like Hoth Therapeutics. This online service, which is a part of our RADR platform, has the potential to be a game-changer in CNS drug development. This cutting-edge AI tool, with its 94% accuracy in predicting blood-brain barrier permeability, is empowering researchers to make faster, smarter decisions, accelerating the path to life-changing therapies for patients worldwide." – Panna Sharma, CEO, Lantern Pharma. Lantern Pharma is a publicly traded company listed on the NASDAQ stock exchange.","length":631,"tagName":"p"},{"type":...